TALAPRO-3 Trial Results for Talazoparib plus Enzalutamide in HRR-Mutant mHSPC - Neeraj Agarwal
Neeraj Agarwal
Neeraj Agarwal discusses TALAPRO-3, a 599-patient phase 3 trial randomizing HRR-mutated metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide plus talazoparib versus ADT plus enzalutamide plus placebo.
PSMAddition Trial of ADT, ARPI, and Lutetium-177 in Metastatic Hormone-Sensitive Prostate Cancer - Fred Saad
Fred Saad
Fred Saad presents a PSMAddition subgroup analysis examining rPFS benefit by disease volume and timing in the trial of ADT plus any ARPI with or without lutetium-177 in metastatic hormone-sensitive prostate cancer.
